CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit declines year over year
Q1 FY2026 gross profit of $10.01M fell 80.3% year over year, behind the -76.1% change in trailing-twelve-month gross profit. Sequentially, it rose 1409.4% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -80.3% toward the trailing-twelve-month pace of -76.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 76.2M USD
- Year-over-year change
- -44.8%
- 4-year CAGR
- +19.5%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.2M | -44.8% |
| FY2024 | 2024-12-31 | 138.1M | +36.4% |
| FY2023 | 2023-12-31 | 101.21M | +90.4% |
| FY2022 | 2022-12-31 | 53.16M | +42.5% |
| FY2021 | 2021-12-31 | 37.31M | — |
Gross Profit vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 gross profit of $35.29M is the 7th highest of the 10 companies compared; the peer median is $71.82M.
- Its year-over-year change of -76.1% is the lowest of 8, against a peer median of +35.8%.
- Gross profit amounts to 99.3% of revenue for CTMX, versus a peer median of 86.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $607.18M | +545.5% | — | 86.5% | |
| LTM Sep 2026 | $182.57M | +35.8% | -36.4% | 68.6% | |
| LTM Mar 2026 | $109.85M | +16.2% | -9.3% | 69.9% | |
| LTM Mar 2026 | $98.33M | +52.1% | +17.0% | 98.7% | |
| LTM Mar 2026 | $71.82M | +2.1% | -29.1% | 90.7% | |
| LTM Jun 2026 | $45.46M | -54.8% | — | 43.3% | |
| LTM Mar 2026 | $35.29M | -76.1% | +12.8% | 99.3% | |
| LTM Mar 2026 | $13.83M | — | — | 99.8% | |
| LTM Jun 2024 | -$118.77K | — | -6.2% | 14.6% | |
| LTM Sep 2026 | -$742K | +99.6% | — | 662.5% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $71.82M | +35.8% | -9.3% | 86.5% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.